Pacira Pharmaceuticals Inc to Post Q3 2018 Earnings of ($0.06) Per Share, Leerink Swann Forecasts (PCRX)

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) – Investment analysts at Leerink Swann issued their Q3 2018 EPS estimates for shares of Pacira Pharmaceuticals in a note issued to investors on Monday, October 15th. Leerink Swann analyst A. Fadia anticipates that the company will earn ($0.06) per share for the quarter. Leerink Swann also issued estimates for Pacira Pharmaceuticals’ FY2018 earnings at ($0.21) EPS, FY2019 earnings at $0.49 EPS, FY2020 earnings at $1.27 EPS, FY2021 earnings at $2.24 EPS and FY2022 earnings at $2.53 EPS.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Thursday, August 2nd. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.37. Pacira Pharmaceuticals had a negative return on equity of 0.39% and a negative net margin of 3.64%. The business had revenue of $84.10 million during the quarter, compared to the consensus estimate of $77.53 million. During the same period last year, the company earned ($0.11) earnings per share. The business’s revenue for the quarter was up 18.6% compared to the same quarter last year.

Several other analysts also recently weighed in on PCRX. Canaccord Genuity set a $34.00 target price on Pacira Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, June 29th. Royal Bank of Canada set a $50.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 2nd. Mizuho restated a “hold” rating and set a $31.00 price target on shares of Pacira Pharmaceuticals in a research note on Friday, June 29th. Bank of America raised their price target on Pacira Pharmaceuticals from $46.00 to $48.00 and gave the company a “neutral” rating in a research note on Wednesday, October 10th. Finally, ValuEngine upgraded Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 21st. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have issued a buy rating to the stock. Pacira Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $48.00.

NASDAQ:PCRX opened at $48.04 on Wednesday. Pacira Pharmaceuticals has a twelve month low of $26.95 and a twelve month high of $52.60. The firm has a market cap of $2.01 billion, a PE ratio of -81.90 and a beta of 1.86. The company has a quick ratio of 7.79, a current ratio of 8.58 and a debt-to-equity ratio of 0.98.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 4,773 shares of Pacira Pharmaceuticals stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $47.04, for a total value of $224,521.92. Following the transaction, the chief accounting officer now owns 22,374 shares in the company, valued at $1,052,472.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Lauren Bullaro Riker sold 1,000 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $50.70, for a total value of $50,700.00. Following the completion of the transaction, the vice president now owns 11,474 shares in the company, valued at approximately $581,731.80. The disclosure for this sale can be found here. Insiders sold 40,502 shares of company stock worth $1,913,864 in the last quarter. 5.90% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Partner Fund Management L.P. grew its stake in Pacira Pharmaceuticals by 82.5% in the second quarter. Partner Fund Management L.P. now owns 3,110,213 shares of the company’s stock valued at $99,682,000 after purchasing an additional 1,405,605 shares during the last quarter. Macquarie Group Ltd. grew its stake in Pacira Pharmaceuticals by 49.4% in the second quarter. Macquarie Group Ltd. now owns 2,321,125 shares of the company’s stock valued at $74,392,000 after purchasing an additional 768,011 shares during the last quarter. Schroder Investment Management Group grew its stake in Pacira Pharmaceuticals by 2.4% in the second quarter. Schroder Investment Management Group now owns 1,255,030 shares of the company’s stock valued at $38,969,000 after purchasing an additional 29,223 shares during the last quarter. Stephens Investment Management Group LLC grew its stake in Pacira Pharmaceuticals by 13.9% in the second quarter. Stephens Investment Management Group LLC now owns 1,198,271 shares of the company’s stock valued at $37,206,000 after purchasing an additional 146,319 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Pacira Pharmaceuticals by 18.5% during the second quarter. Millennium Management LLC now owns 1,052,503 shares of the company’s stock worth $33,733,000 after acquiring an additional 164,112 shares during the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Featured Story: Fundamental Analysis and Individual Investors

Earnings History and Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply